Toyota's gasoline-electric hybrid models are in high demand worldwide, causing significant shortages and long wait times for buyers. Due to this surge, parts suppliers are struggling to keep up, leading to delays of up to several months in markets like the U.S., Japan, China, and Europe. In Europe, customers are waiting up to 70 days for popular models like the Yaris Cross hybrid and RAV4 plug-in hybrid, a sharp increase from previous years.
Global hybrid sales have almost tripled in the last five years, with sales reaching 16.1 million, confirming Toyota’s successful bet on hybrid technology over battery-only electric vehicles (EVs). However, the strong demand is stretching Toyota's production capacity. A shortage of key components, such as magnets for hybrid motors and inverters, is contributing to these delays, especially with major suppliers like Aisin and Denso facing bottlenecks.
To address this, Toyota is adding manufacturing capacity in India, aiming to produce an additional 132,000 vehicles annually. It has also invested $14 billion in a North Carolina battery plant to meet North American hybrid demand. Meanwhile, competitors like Hyundai and Kia are also grappling with hybrid production delays due to limited capacity.
While these supply challenges persist, hybrids continue to offer a fuel-efficient alternative to traditional vehicles, with many customers willing to wait for delivery due to the significant fuel savings they provide. As Toyota works to streamline its production, the company remains committed to meeting global demand for its hybrid vehicles.


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 



